[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
Hutchmed (china) Limited LSE:HCM London Ordinary Share KYG4672N1198 ORD USD0.10
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  3.50 0.75% 472.00 469.00 472.00 481.50 468.00 472.00 42,962 16:29:50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 166.7 -138.8 -13.2 - 4,080

Hutchmed (china) Share Discussion Threads

Showing 3451 to 3472 of 3525 messages
Chat Pages: 141  140  139  138  137  136  135  134  133  132  131  130  Older
DateSubjectAuthorDiscuss
10/8/2021
10:08
Getting some nice coverage in the trade press on the Epizyme deal Https://www.thepharmaletter.com/article/epizyme-strikes-deal-with-hutchmed-for-tazverik-in-greater-china?mc_cid=735defc592&mc_eid=4e03c8866d
nerdofsteel
10/8/2021
09:01
And sense a break of 650p is getting closer and closer. After many years price momentum seems to be building.
its the oxman
10/8/2021
07:07
HUTCHMED is uniquely positioned to make the most of TAZVERIK® Summary rationale *ES = epithelioid sarcoma, a solid tumor; FL = follicular lymphoma, a hematological malignancy –a subtype of non-Hodgkin’s lymphoma. Global First-in-Class Product First and only US FDA approved EZH2 inhibitor 1stapprovals in Jan & Jun 2020, for ES & FL* Accelerates China Hematology Commercialization Advances build-out of hematology sales team–ahead of potential launches of 5 clinical assets Manufacturing expertise & capabilities–substantial and growing infrastructure Pipeline Synergy Broad PotentialApplicability Inhibit epigenetics inhibit cell proliferation–EZH2 allows transcription of genes involved in cell functions such as cell cycle control and terminal differentiation Highly favorable safety profile–potential combos across HUTCHMED portfolio This is a very good stategic play for Hutchmed. We have to hope Epizyme's viability continues, which it should as U.S. sales really start to take off this year.
nerdofsteel
09/8/2021
15:35
NofS - Have you changed your name here to yidarmyTom? LSE postings would tend to support this conclusion. Good meeting just completed. Looks like this is a specific product that HCM are interested in and for now the net is not being cast for more like it just now. Opportunity and the great safety profile of TAZVERIK® made it a worthy candidate. Look forward to more developments as they come.
lauders
09/8/2021
10:58
I think today's deal on TAZVERIK® gives Hutchmed a great opportunity top leverage its sales teams and other infrastructure in China to market drugs owned by Companies who want to partner and who have no resoyrce in region, or cannot navigate the Chinese Regulatory system. Beigene have made a great success of it. TAZVERIK® is forecast to exceed $900m pa peak sales in the U.S. so it could approach that in what is a larger chinese market, even with NRDL discounts. I'm looking forward to the Company's view on forecast peak sales on the conference call today. I can seem more of these licencing deals coming our way. I also look froward to increased revenue forecasts from Analysts. Https://www.prnewswire.com/news-releases/global-ezh2-inhibitor-market-report-2021-dosage-price--sales-analysis-of-tazverik-tazverik-sales-opportunity-of-900-million-forecast-to-2026-7-drugs-in-clinical-trial-301349536.html
yidarmytom
09/8/2021
08:53
Shares up a tad so guess it's perceived as a positive.
its the oxman
09/8/2021
02:10
An RNS to come today from the looks of things: Https://www.hutch-med.com/wp-content/uploads/2021/08/a210809.pdf HUTCHMED and Epizyme Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® (tazemetostat) in Greater China – Collaboration designed to accelerate global development and investigate TAZVERIK® combinations with HUTCHMED’s novel oncology medicines portfolio – – Epizyme to receive US$25 million upfront payment and up to US$285 million in potential milestone payments, together with additional tiered royalties; HUTCHMED to receive development and commercial rights to TAZVERIK® in Greater China – – HUTCHMED to host a webcast and call on Monday, August 9, at 9:30 a.m. EDT / 2:30 p.m. BST / 9:30 p.m. HKT – see www.hutch-med.com/event for details –
lauders
02/8/2021
10:51
Nahoon, agree US talking it’s own book hard in my opinion. China moves to regulate tech business, Bitcoin etc and it’s called everything from government manipulation to a covert strike against the western world . US moves to regulate Tech business, Bitcoin etc and it’s applauded as much over due necessity. Blatantly holds up approval of Astrazenica COVID vaccine whilst it’s own pharmas price gouge its own people and now the rest of the world and so forth. Business as usual then..
dbadvn
02/8/2021
09:15
I feel we're doing exceptionally well considering all the anti-Chinese sentiment around at the moment.
nahoon
02/8/2021
01:57
NofS - A spammer who posted on numerous boards around the time of the post. Automatically on my filter list when such folk appear. Best not to engage with them. Best just concentrate on the news flow like this: Https://www.ii.co.uk/analysis-commentary/why-city-happy-astrazenecas-results-ii520987 29th July AstraZeneca, meanwhile, has had a positive influence on the valuation of the biggest stock on AIM, biotech business HUTCHMED (China) Ltd HCM 0.51%. Its shares rose another 9% or 52p to a fresh record of 630p after well-received interim results on Wednesday alongside the disclosure it has started a phase two trial of oncology drug Orpathys with Astra. HutchMed's valuation is now close to £5 billion, having been given a boost by a move to raise $615 million (£443 million) through the IPO of 104 million new shares in a primary listing in Hong Kong. The company now has three approved oncology drugs in China and is making significant inroads to approvals in Europe and the US. The shares originally listed on AIM as Hutchison China MediTech in 2007 and generated big profits for those early backers who spotted the company's potential in China, where there are large unmet medical needs and a quarter of the world's cancer patients.
lauders
01/8/2021
20:22
explain the relevance to Hutchmed please, Thank You
nerdofsteel
31/7/2021
04:21
Nice short interview here by CH: Https://twitter.com/hutchmed/status/1421025574265360385/photo/1 Https://www.bloomberg.com/news/videos/2021-07-29/health-care-biotech-are-highly-regulated-globally-hutchmed-video Innovative drugs are safe(r) from Chinese regulation and "interference" than generic.
lauders
31/7/2021
02:11
So much for global markets! More like "So much for efficient markets!" LOL Will be nice to see HCM over 700p one of these coming days.
lauders
29/7/2021
21:25
That’s a very sad sjack. Usd close at near as 41usd, hk at almost 50usd. More than 20% difference. So much for global markets!
dbadvn
29/7/2021
20:45
You’re not going to have your top marketmaker mechanics making a book in a relatively lowly traded AIM stock like Hutchmed.The name of the game is to keep a low profile,monkey with a wide spread and wait to sneak under the umbrella afforded by the Nasdaq market.Marketmakers are invariably little more than day traders,happy to trot off to the bar of an evening with a square book .Their advantage is being able to accurately gauge the sentiment surrounding a stock as a result of handling,observing order flow.A weather vane of sorts.This doesn’t make them clever so much as relatively privileged due to delayed order reporting etc.They have the easy access and cost advantages of being able to exploit potential arbitrage opportunities but at the end of the day,they’d rather make a few quid crossing a million Astra Zeneca for a tenth of a penny.
steeplejack
29/7/2021
15:26
As always, a license to print money!
fionascott1234
29/7/2021
15:24
Sportii, can't be that clever if they allow a 17% arbitrage opportunity to pass them by...
dbadvn
29/7/2021
15:18
right now (1515 BST) HK closing price is USD 49.95 equivalent and Nasdaq price is USD 41.33, 17% difference. Amazing !
dbadvn
29/7/2021
15:12
ADRs improve once the aim market closes. This phenomenon has become a norm! MMs are a clever bunch.
sportii
29/7/2021
15:11
Chester, agree. For nearly 5 hours there was an almost 15% gap in the Hk and the Us price - surely someone with the right market access could arbitrage that successfully. Need someone with real trading knowledge but suspect the ADR / DI structure of the public holdings mean that their is a structural barrier to buying in the US and selling in HK If the gap persists and gets wider I assume the company will have to comment and make some move to close it although not clear how they can.
dbadvn
29/7/2021
14:52
The market is very strange London 9% up to 2:30 then NASDAQ opens and it loses 6% in 5 minutes. Hong Kong has it at over £7?Is this supply and demand on shares in HK as differential is mad. Does this make sense to someone?
chester9
29/7/2021
09:04
Closing around 76HK.Our AIM marketmakers continue to pay homage to the nasdaq quote.The AIM marketmakers could well be short.There's a real reluctance to follow the HK price hike and that sometimes indicates a desire to hose down enthusiasm until they get square ie a bit like Goldmans refusing to correctly price subprime in 2008 until they themselves were short.Speculation on my part.I appreciate the AIM market affording buying opportunities.
steeplejack
Chat Pages: 141  140  139  138  137  136  135  134  133  132  131  130  Older
ADVFN Advertorial
Your Recent History
LSE
HCM
Hutchmed (..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20211018 22:41:35